Atacama Labs Oy has developed an oral drug delivery technology (called ‘pneumatic dry granulation’ or ‘PDG Technology. The technology is aimed at replacing existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.
The Excella and Atacama Labs partnership will offer a cGMP compliant and FDA / EMEA / Anvisa certified environment to house Atacama’s innovative and fully automated PDG equipment.
Mittwich, CEO of the Atacama Labs, said: “We can develop almost any API (including difficult ones) into higher drug load tablets with good hardness and dissolution profiles and our clients can profit from new tablet characteristics to extend the life cycle of expiring drugs, which can mean several more years of protected sales of a blockbuster drug. In both cases, global economics can be hundreds of millions of additional revenue, naturally subject to magnitude of drug revenue.”